High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal
暂无分享,去创建一个
M. Reeves | Matthew J. Selleck | M. Senthil | Elizabeth R. Raskin | J. Morgan | S. Lum | F. Luca | B. Jabo | C. Garberoglio | A. Choi | B. Babcock | Mayada Aljehani
[1] F. Quereshy,et al. Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. , 2016, Current oncology.
[2] S. Freels,et al. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer , 2016, Cancer.
[3] N. Kim,et al. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer , 2016, Journal of Cancer Research and Clinical Oncology.
[4] J. Pruijt,et al. Adjuvant chemotherapy is not associated with improved survival for all high‐risk factors in stage II colon cancer , 2016, International journal of cancer.
[5] Aalok Kumar,et al. Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer , 2015, Cancer.
[6] C. Lohse,et al. Predictors of recurrence free survival for patients with stage II and III colon cancer , 2014, BMC Cancer.
[7] Maureen A. Smith,et al. Adjuvant Chemotherapy for Stage II Right-Sided and Left-Sided Colon Cancer: Analysis of SEER-Medicare Data , 2014, Annals of Surgical Oncology.
[8] B. Karabulut,et al. Do High-risk Features Support the Use of Adjuvant Chemotherapy in Stage II Colon Cancer? A Turkish Oncology Group Study , 2014, Tumori.
[9] E. Guinó,et al. Clinicopathological risk factors of Stage II colon cancer: results of a prospective study , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[10] K. Shirouzu,et al. High‐risk stage II colon cancer after curative resection , 2011, Journal of surgical oncology.
[11] T. Hickish,et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Gonen,et al. Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy , 2008, Diseases of the colon and rectum.
[13] D. Kerr,et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.
[14] R. Greil,et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer , 2007, British Journal of Cancer.
[15] V. Moyer,et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. , 2007, Journal of the National Cancer Institute.
[16] M. Somerfield,et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Catalano,et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. P. Pignon,et al. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.
[19] C. Compton,et al. The Prognosis of T3N0 Colon Cancer Is Dependent on the Number of Lymph Nodes Examined , 2003, Annals of Surgical Oncology.